DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
6751 Steger Drive	2/12/2018-2/16/2018			
Cincinnati, OH 45237-3097	FEI NUMBER			
(513)679-2700 Fax:(513)679-2772	3009988995			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED				
Raymond R. Carlson, Pharmacist/Owner	£°			
FIRM NAME	STREET ADDRESS			
RC Compounding Services, LLC	3030 Center Rd			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Poland, OH 44514-2158	Producer of Sterile Drug Products			

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1

Personnel placed equipment/supplies in an area that blocked the movement of first pass air around an open unit, either before or after it was filled with sterile product.

Specifically,

On 02/12/2018, during the observation of production of Serum Tears in the ISO 5 Laminar Air Flow Hood, we observed an employee remove the caps from sterile droptainers and place the caps and containers in a pile, blocking the first pass ISO 5 air flow.

OBSERVATION 2

Disinfecting agents and cleaning wipes used in the ISO 5 classified aseptic processing areas were not sterile.

Specifically,

A. On 02/13/2018, we observed an employee use non-sterile (b) (4) to clean the ISO 5 Laminar Air Flow Hood. The employee was observed spraying a sterile wipe with non-sterile (b) (4) and then cleaning the work surface and sides inside of the ISO 5 Laminar Air Flow Hood.

the set of	EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator Jazmine N Still, Investigator Signed by Mathew B Casale Investigator Signed by Mathew B. Casale Investigator Signed by Mathew B. Casale Investigator Signed by Mathew B. Casale Investigator		DATE ISSUED	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATION	ONS	PAGE 1 OF 4 PAGES

	HEALTH AND HUMAN SERVICES
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION
6751 Steger Drive	2/12/2018-2/16/2018
Cincinnati, OH 45237-3097	FEI NUMBER 3009988995
(513)679-2700 Fax:(513)679-2772	
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	
Raymond R. Carlson, Pharmacist/Owner	
FIRM NAME	STREET ADDRESS
RC Compounding Services, LLC	3030 Center Rd
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED
Poland, OH 44514-2158	Producer of Sterile Drug Products
OBSERVATION 3	
OBSERVATION 3 Personnel donned gowning apparel improperly	
become contaminated	y, in a way that may have caused the gowning apparel to
become contaminated.	y, in a way that may have caused the gowning apparel to
	y, in a way that may have caused the gowning apparel to
become contaminated. Specifically,	y, in a way that may have caused the gowning apparel to
Specifically, On 02/12/2018, we observed an employee don	n non-sterile gloves; then put on sterile sleeves, touching the non-sterile gloves, exposing bare hands; don sterile
Specifically, On 02/12/2018, we observed an employee don them with the non-sterile gloves; then remove	n non-sterile gloves; then put on sterile sleeves, touching the non-sterile gloves, exposing bare hands; don sterile products.
Specifically, On 02/12/2018, we observed an employee don them with the non-sterile gloves; then remove gloves; and then begin producing sterile drug p OBSERVATION 4	n non-sterile gloves; then put on sterile sleeves, touching the non-sterile gloves, exposing bare hands; don sterile products.

B) On 02/13/2018, we observed an employee spray the pH electrode with (b) (4) water and then measure the pH of epinephrine solution in the ISO 7 cleanroom before using it in production of

	EMPLOYEE(S) SIGNATURE Matthew B Casale, Investigator Jazmine N Still, Investigator Signed for Value B Casale N Still, Signed 02-16-2018 1743 16		DATE ISSUED	
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	NS	PAGE 2 OF 4 PAGES

DATE(S) OF INSPECTION 2/12/2018-2/16/2018 FEI NUMBER 3009988995	
FEINUMBER	
3009988995	
STREET ADDRESS	
3030 Center Rd	
TYPE ESTABLISHMENT INSPECTED	
Producer of Sterile Drug Products	

syringes of sterile Epinephrine/Lidocaine Intraocular Solution 0.01 mg: 20 mg/ml. The (b) (4) water is poured into a non-sterile spray bottle in the ISO 7 anteroom before it is used to spray the pH electrode.

OBSERVATION 5

Your facility design allowed the influx of poor quality air into a higher classified area.

Specifically,

- A. There are no air returns in the ISO 7 cleanroom or ISO 7 anteroom. Strong palpable air flow can be felt at the top, bottom, and sides of the doors exiting the cleanroom to the anteroom and the anteroom to the unclassified area.
- B. There is no evidence that the ISO 7 anteroom was qualified while the wall mounted air conditioner was in operation to demonstrate that the air conditioner does not affect the air quality in the ISO 7 anteroom.

OBSERVATION 6

You produced highly potent drugs without providing adequate containment, cleaning of work surfaces and cleaning of personnel to prevent cross-contamination.

Specifically,

A. Sterile hazardous drugs such as tacrolimus, testosterone, and progesterone are produced in the same ISO 5 Laminar Air Flow Hood as all other sterile drug products with only a (b) (4)
(b) (4) decontamination step in between hazardous and non-hazardous drug production.

	EMPLOYEE(S) SIGNATURE Matthew B Casale, Jazmine N Still, 3		Matthew B Casale Investigator Signed By Matthew B. Casale -S Date Signed 02-16-2018 17 43 16	DATE ISSUED 2/16/2018
FORM FDA 483 (09/08)	PREVIOUS EDITION OBSOLETE	INSPECTIONAL OBSERVATIO	DNS	PAGE 3 OF 4 PAGES